| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2006.
NEWS |
Sometimes Size Doesn't Matter: Reevaluating RECIST and Tumor Response Rate Endpoints
| The first 150 words of the full text of this article appear below. |
If you give a cancer patient a drug and then the tumor's growth screeches to a halt or a hole appears in its middle, most people would say the drug was working. But on the basis of the response criteria most widely used for solid tumors, these changes mean nothing.
Standardized response criteria are critical for directing individual patient care, evaluating new therapies, and communicating risk to family and patients. Yet just what those criteria should be for solid tumors is up for debate. Although some groups are looking for new ways to physically measure success, others are moving away from tumor measurements altogether and strictly examining survival.
"I think standardizing response assessment is generally a good thing because people speak the same language when they are reporting studies," said Primo N. Lara, M.D., associate professor of medicine at the University of California at Davis in Sacramento, who presented on
Choi Criteria Trump RECIST?
A New Look at Tumor Response
The old
The new
Another Group's Search
Resisting Tumor Measures
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hajitou, D. C. Lev, J. A. F. Hannay, B. Korchin, F. I. Staquicini, S. Soghomonyan, M. M. Alauddin, R. S. Benjamin, R. E. Pollock, J. G. Gelovani, et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging PNAS, March 18, 2008; 105(11): 4471 - 4476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Suzuki, H. Jacobsson, T. Hatschek, M. R. Torkzad, K. Boden, Y. Eriksson-Alm, E. Berg, H. Fujii, A. Kubo, and L. Blomqvist Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations RadioGraphics, March 1, 2008; 28(2): 329 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Evilevitch, W. A. Weber, W. D. Tap, M. Allen-Auerbach, K. Chow, S. D. Nelson, F. R. Eilber, J. J. Eckardt, R. M. Elashoff, M. E. Phelps, et al. Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., February 1, 2008; 14(3): 715 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, P. M. Arlen, and J. L. Gulley Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design ASCO Educational Book, January 1, 2008; 2008(1): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schlom, P. M. Arlen, and J. L. Gulley Cancer Vaccines: Moving Beyond Current Paradigms Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782. [Abstract] [Full Text] [PDF]
|
|